Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
gptkb:pegfilgrastim
|
| gptkbp:administrativeDivision |
once per chemotherapy cycle
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Neulasta
|
| gptkbp:clinicalTrials |
Phase III trials
reduces infection risk chemotherapy-induced neutropenia NCCN_guidelines |
| gptkbp:community_service |
available
|
| gptkbp:compatibleWith |
certain medications
|
| gptkbp:contraindication |
skin rash
anaphylaxis thrombocytopenia hypersensitivity to pegfilgrastim peripheral edema dyspnea |
| gptkbp:dosageForm |
injection
|
| gptkbp:drugInterdiction |
prescription only
colony-stimulating factor |
| gptkbp:endOfLife |
15 to 80 hours
|
| gptkbp:formulation |
single-use prefilled syringe
multi-dose vial |
| gptkbp:hasPopulation |
cancer patients
|
| gptkbp:healthcare |
adults and children
injection technique side effects awareness when to seek medical help |
| https://www.w3.org/2000/01/rdf-schema#label |
Neulasta
|
| gptkbp:interactsWith |
certain chemotherapy drugs
|
| gptkbp:is_monitored_by |
complete blood count
|
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:lastProduced |
2002
|
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:market |
global
|
| gptkbp:marketedAs |
gptkb:Neulasta_Onpro
|
| gptkbp:numberOfStudents |
urine
|
| gptkbp:offers |
varies by location
|
| gptkbp:researchInterest |
ongoing studies
|
| gptkbp:route |
subcutaneous
|
| gptkbp:safetyFeatures |
acute respiratory distress syndrome
leukocytosis splenic rupture |
| gptkbp:sells |
gptkb:pegfilgrastim
|
| gptkbp:sideEffect |
fatigue
headache nausea bone pain |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
stimulates_bone_marrow
|
| gptkbp:type |
gptkb:pegfilgrastim
|
| gptkbp:usedFor |
preventing infections
|